Integrate the quality management systems operations across the global enterprise, fostering compliance with GxP.
Pharmaceutical and Biotechnology companies are challenged with the ability to deliver operational excellence with full traceability and to efficiently manage the ever changing global regulatory environment. License to Cure for BioPharma is an Industry Solution Experience that uniquely provides the ability to accelerate therapeutic development, approval, manufacturing, and supply, in a global landscape by leveraging an extensive, connected and comprehensive regulatory and quality platform.
License to Cure for BioPharma provides digital continuity for organizations to manage the complexity of an ever increasing number of medicinal products with a single version of the truth based on IDMP standards and enables change impact analysis, informed decision making and full IP reuse to deliver quality best practices shifting the paradigm of regulatory as a constraint to regulatory as an asset.
Benefits of License to Cure for BioPharma
Reduce time to market and cost of market expansion in BioPharma
Transition from a traditional product oriented model to the delivery of therapeutic solutions using a system that enables companies to be more reactive to quickly meet today's market needs.
Leverage Regulatory Intelligence to Drive Your Global Strategy in BioPharma
Spend less time, reduce the risk of non-compliance, improve traceability and accelerate global expansion
Enhance Decision-Making in BioPharma
Enhance decision-making through real-time views across the lifecycle of innovation
Ensure a consistent approach to quality, compliance, and regulatory activities for BioPharma
The 3DEXPERIENCE® platform enables businesses to transition from historical and outdated practices to a connected and transformative environment across your extended ecosystem.
Included in License to Cure for BioPharma
Accelerate therapeutic approval, production, and patient adoption in a global landscape